middle.news
How Biotron’s $1.27M Raise Fuels Next-Gen Antiviral Ambitions
1:16am on Saturday 30th of August, 2025 AEST
•
Biotechnology
Read Story
How Biotron’s $1.27M Raise Fuels Next-Gen Antiviral Ambitions
1:16am on Saturday 30th of August, 2025 AEST
Key Points
Net loss narrowed by over 90% to $318,572
Raised $1.27 million through renounceable rights issue
Received $1.81 million R&D tax incentive rebate
Progress on lead antiviral BIT225 and Hepatitis B preclinical studies
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE